TrialScientific reports2015

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer.

Daniel H Ahn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.